Cargando…

Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint Inhibition

PURPOSE: Prior studies have mixed conclusions about the efficacy and central nervous system (CNS) toxicity profile of combining radiosurgery with anti-programed cell death 1 (PD-1) immune checkpoint inhibition (ICI) for brain metastases. This study evaluates the safety and efficacy of combined radio...

Descripción completa

Detalles Bibliográficos
Autores principales: Travis, Roman L., Marcrom, Samuel R., Brown, Matthew H., Patel, Mayank P., Markert, James M., Riley, Kristen O., Conry, Robert, Willey, Christopher D., Bredel, Markus, Fiveash, John B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897762/
https://www.ncbi.nlm.nih.gov/pubmed/33665483
http://dx.doi.org/10.1016/j.adro.2020.08.017
_version_ 1783653732614930432
author Travis, Roman L.
Marcrom, Samuel R.
Brown, Matthew H.
Patel, Mayank P.
Markert, James M.
Riley, Kristen O.
Conry, Robert
Willey, Christopher D.
Bredel, Markus
Fiveash, John B.
author_facet Travis, Roman L.
Marcrom, Samuel R.
Brown, Matthew H.
Patel, Mayank P.
Markert, James M.
Riley, Kristen O.
Conry, Robert
Willey, Christopher D.
Bredel, Markus
Fiveash, John B.
author_sort Travis, Roman L.
collection PubMed
description PURPOSE: Prior studies have mixed conclusions about the efficacy and central nervous system (CNS) toxicity profile of combining radiosurgery with anti-programed cell death 1 (PD-1) immune checkpoint inhibition (ICI) for brain metastases. This study evaluates the safety and efficacy of combined radiosurgery and anti-PD-1 ICI for melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) brain metastases (BM). METHODS AND MATERIALS: Forty-one patients with 153 radiation naïve melanoma BM and 33 patients with 118 BM of NSCLC and RCC origin from 2014 through 2019 received radiosurgery and either anti PD-1 receptor inhibition or anti PD-L1 inhibition targeting the PD-1 ligand with less than 4 months separating either therapy. Similar to Radiation Therapy Oncology Group 9005, high-grade CNS toxicity was defined as irreversible grade 3 or any grade 4/5 neurologic event. Salvage resection revealing necrosis and viable tumor was considered grade 4 toxicity and local failure. An increase in greatest cross-sectional diameter of 25% on contrasted magnetic resonance imaging was designated as a local failure. RESULTS: Median follow-up was 10 months (range, 1-41 months). Local control was estimated to be 90.3% at 1 year. Distant control was 38.8% at 1 year, and neither local nor distant control were significantly influenced by limiting steroids to the day of treatment (P = .55, .52 respectively). One-year freedom from high-grade toxicity was 90.4% for patients and 94.6% for tumors. Though melanoma accounted for 41 (55%) patients and 153 (56%) tumors, it accounted for all high-grade toxicities (P = .03). These patients had some combination of high tumor burden, aggressive steroid taper, and treatment with ipilimumab. CONCLUSIONS: Stereotactic radiosurgery combined with anti-PD-1 ICI appears to result in a high rate of local tumor control and a low rate of high-grade CNS toxicity, comparable to historical series with radiosurgery alone. High-grade toxicity is more likely in melanoma than RCC and NSCLC. Coming prospective studies will shed light on further questions about treatment timing, steroids, and response.
format Online
Article
Text
id pubmed-7897762
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78977622021-03-03 Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint Inhibition Travis, Roman L. Marcrom, Samuel R. Brown, Matthew H. Patel, Mayank P. Markert, James M. Riley, Kristen O. Conry, Robert Willey, Christopher D. Bredel, Markus Fiveash, John B. Adv Radiat Oncol Clinical Investigation PURPOSE: Prior studies have mixed conclusions about the efficacy and central nervous system (CNS) toxicity profile of combining radiosurgery with anti-programed cell death 1 (PD-1) immune checkpoint inhibition (ICI) for brain metastases. This study evaluates the safety and efficacy of combined radiosurgery and anti-PD-1 ICI for melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) brain metastases (BM). METHODS AND MATERIALS: Forty-one patients with 153 radiation naïve melanoma BM and 33 patients with 118 BM of NSCLC and RCC origin from 2014 through 2019 received radiosurgery and either anti PD-1 receptor inhibition or anti PD-L1 inhibition targeting the PD-1 ligand with less than 4 months separating either therapy. Similar to Radiation Therapy Oncology Group 9005, high-grade CNS toxicity was defined as irreversible grade 3 or any grade 4/5 neurologic event. Salvage resection revealing necrosis and viable tumor was considered grade 4 toxicity and local failure. An increase in greatest cross-sectional diameter of 25% on contrasted magnetic resonance imaging was designated as a local failure. RESULTS: Median follow-up was 10 months (range, 1-41 months). Local control was estimated to be 90.3% at 1 year. Distant control was 38.8% at 1 year, and neither local nor distant control were significantly influenced by limiting steroids to the day of treatment (P = .55, .52 respectively). One-year freedom from high-grade toxicity was 90.4% for patients and 94.6% for tumors. Though melanoma accounted for 41 (55%) patients and 153 (56%) tumors, it accounted for all high-grade toxicities (P = .03). These patients had some combination of high tumor burden, aggressive steroid taper, and treatment with ipilimumab. CONCLUSIONS: Stereotactic radiosurgery combined with anti-PD-1 ICI appears to result in a high rate of local tumor control and a low rate of high-grade CNS toxicity, comparable to historical series with radiosurgery alone. High-grade toxicity is more likely in melanoma than RCC and NSCLC. Coming prospective studies will shed light on further questions about treatment timing, steroids, and response. Elsevier 2020-09-16 /pmc/articles/PMC7897762/ /pubmed/33665483 http://dx.doi.org/10.1016/j.adro.2020.08.017 Text en © 2020 Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Clinical Investigation
Travis, Roman L.
Marcrom, Samuel R.
Brown, Matthew H.
Patel, Mayank P.
Markert, James M.
Riley, Kristen O.
Conry, Robert
Willey, Christopher D.
Bredel, Markus
Fiveash, John B.
Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint Inhibition
title Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint Inhibition
title_full Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint Inhibition
title_fullStr Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint Inhibition
title_full_unstemmed Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint Inhibition
title_short Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint Inhibition
title_sort control and toxicity in melanoma versus other brain metastases in response to combined radiosurgery and pd-(l)1 immune checkpoint inhibition
topic Clinical Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897762/
https://www.ncbi.nlm.nih.gov/pubmed/33665483
http://dx.doi.org/10.1016/j.adro.2020.08.017
work_keys_str_mv AT travisromanl controlandtoxicityinmelanomaversusotherbrainmetastasesinresponsetocombinedradiosurgeryandpdl1immunecheckpointinhibition
AT marcromsamuelr controlandtoxicityinmelanomaversusotherbrainmetastasesinresponsetocombinedradiosurgeryandpdl1immunecheckpointinhibition
AT brownmatthewh controlandtoxicityinmelanomaversusotherbrainmetastasesinresponsetocombinedradiosurgeryandpdl1immunecheckpointinhibition
AT patelmayankp controlandtoxicityinmelanomaversusotherbrainmetastasesinresponsetocombinedradiosurgeryandpdl1immunecheckpointinhibition
AT markertjamesm controlandtoxicityinmelanomaversusotherbrainmetastasesinresponsetocombinedradiosurgeryandpdl1immunecheckpointinhibition
AT rileykristeno controlandtoxicityinmelanomaversusotherbrainmetastasesinresponsetocombinedradiosurgeryandpdl1immunecheckpointinhibition
AT conryrobert controlandtoxicityinmelanomaversusotherbrainmetastasesinresponsetocombinedradiosurgeryandpdl1immunecheckpointinhibition
AT willeychristopherd controlandtoxicityinmelanomaversusotherbrainmetastasesinresponsetocombinedradiosurgeryandpdl1immunecheckpointinhibition
AT bredelmarkus controlandtoxicityinmelanomaversusotherbrainmetastasesinresponsetocombinedradiosurgeryandpdl1immunecheckpointinhibition
AT fiveashjohnb controlandtoxicityinmelanomaversusotherbrainmetastasesinresponsetocombinedradiosurgeryandpdl1immunecheckpointinhibition